3 small-caps to buy after today’s results?

Could these three smaller companies be something special?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Henry Boot (LSE: BHY) reported a strong performance in its half-year results this morning. The group, whose operations extend across housebuilding, commercial development, construction and plant hire, said pre-tax profit advanced 49% on increased revenue of 35%.

The shares have moved higher in early trading, and at 208p are back to their pre-referendum level. Management said that so far since the Brexit vote it’s been business-as-usual, but what I particularly liked was the following comment.

“The completion of our commercial development pipeline in progress, largely already pre-let and/or pre-sold is likely to see the Group be cash generative over the next two years and, should the post referendum world prove to be more turbulent than we are experiencing at the moment, these internally generated funds should provide the resources to acquire competitively priced opportunities for the next cyclical growth phase”.

Trading on a price-to-earnings (P/E) ratio of just 9.9, an attractive price-to-earnings growth (PEG) ratio of 0.5, and with a handy 3.2% dividend yield, this looks a very buyable stock to my eye.

Bright outlook

Improved commodities prices and a weaker pound have led to a brighter outlook for global natural resources royalty company Anglo Pacific (LSE: APF). Management reported a solid start to the year in its interim results this morning, and said that as things stand, the company expects royalty income for the full year to be significantly higher than in 2015.

The shares, which had reached a low of not much more than 50p earlier this year, are now up to 97p — bang in line with the net asset value (NAV) reported this morning. However, the directors state that they consider the value of a number of assets to be higher than that recorded on the balance sheet (three times higher in one case), so the stock still appears to be at a discount to inherent NAV.

Combine the attractive asset picture with a forward 6.2% dividend yield and a forecast 2016/17 PEG of just 0.2 and this is another share I currently rate as a buy.

Speculative opportunity

There was little we didn’t already know in this morning’s half-year results from Optibiotix Health (LSE: OPTI). The company, whose patent-protected compounds change the way microbes in the body work and interact, has a growing portfolio of products reaching commercialisation in high public interest areas including obesity, high cholesterol and diabetes.

Optibiotix already has commercial agreements with the brand owners of Slimfast and with DSM, the world’s leading supplier of nutritional ingredients. The company added today that commercial discussions with further potential partners across both consumer and pharma “have indicated a wider range of opportunities than initially envisaged,” and that it expects to report on these commercial discussions in the coming months.

Optibiotix is lossmaking at this stage in its life (£0.61m in the first half) but has cash of £3.55m, which it says is sufficient to fund its existing research and development programmes.

I’m not generally keen on ‘blue-sky’ companies, but Optibiotix’s business and market opportunities are relatively easy to understand, there’s clearly significant commercial interest in its products, and the company could rapidly grow into — or exceed — it’s current valuation of £61m at a share price of 70p. As such, I rate the stock as one of the better speculative buys in the market.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK owns shares of Anglo Pacific. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Is the S&P 500 going to 10,000 by 2030? This expert thinks so

One stock market strategist sees animal spirits taking hold and driving the S&P 500 index even higher by the end…

Read more »